Literature DB >> 25546814

Melatonin treatment improves primary progressive multiple sclerosis: a case report.

Antonio López-González1, Nuria Álvarez-Sánchez, Patricia J Lardone, Ivan Cruz-Chamorro, Alicia Martínez-López, Juan M Guerrero, Russel J Reiter, Antonio Carrillo-Vico.   

Abstract

We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  melatonin; multiple sclerosis; primary progressive multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25546814     DOI: 10.1111/jpi.12203

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  14 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 2.  The potential roles of amino acids and their major derivatives in the management of multiple sclerosis.

Authors:  Somayeh Pashaei; Reza Yarani; Pantea Mohammadi; Mohammad Sajad Emami Aleagha
Journal:  Amino Acids       Date:  2022-04-26       Impact factor: 3.520

Review 3.  Melatonin as a mitochondria-targeted antioxidant: one of evolution's best ideas.

Authors:  Russel J Reiter; Sergio Rosales-Corral; Dun Xian Tan; Mei Jie Jou; Annia Galano; Bing Xu
Journal:  Cell Mol Life Sci       Date:  2017-09-01       Impact factor: 9.261

4.  Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.

Authors:  Jie Wen; Prasanth S Ariyannur; Rachel Ribeiro; Mikiei Tanaka; John R Moffett; Batool F Kirmani; Aryan M A Namboodiri; Yumin Zhang
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-25       Impact factor: 4.147

Review 5.  Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics.

Authors:  Dun-Xian Tan; Lucien C Manchester; Lilan Qin; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2016-12-16       Impact factor: 5.923

Review 6.  Western lifestyle and immunopathology of multiple sclerosis.

Authors:  Olga Matveeva; Jeroen F J Bogie; Jerome J A Hendriks; Ralf A Linker; Aiden Haghikia; Markus Kleinewietfeld
Journal:  Ann N Y Acad Sci       Date:  2018-01-27       Impact factor: 5.691

Review 7.  Mitochondria: Central Organelles for Melatonin's Antioxidant and Anti-Aging Actions.

Authors:  Russel J Reiter; Dun Xian Tan; Sergio Rosales-Corral; Annia Galano; Xin Jia Zhou; Bing Xu
Journal:  Molecules       Date:  2018-02-24       Impact factor: 4.411

Review 8.  Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells.

Authors:  George Anderson; Moses Rodriguez; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

Review 9.  Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway.

Authors:  Majid Ghareghani; Russel J Reiter; Kazem Zibara; Naser Farhadi
Journal:  Front Immunol       Date:  2018-10-30       Impact factor: 7.561

Review 10.  Pineal Calcification, Melatonin Production, Aging, Associated Health Consequences and Rejuvenation of the Pineal Gland.

Authors:  Dun Xian Tan; Bing Xu; Xinjia Zhou; Russel J Reiter
Journal:  Molecules       Date:  2018-01-31       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.